<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04810793</url>
  </required_header>
  <id_info>
    <org_study_id>2020-SDU-QILU-G101</org_study_id>
    <nct_id>NCT04810793</nct_id>
  </id_info>
  <brief_title>The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure</brief_title>
  <official_title>The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Taian City Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dezhou People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weifang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengli Oilfield Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The patients who accepted the quadruple eradication program of the helicobacter pylori but&#xD;
      failed to eradicate helicobacter pylori will be assessed the most suitable re-eradication&#xD;
      time of helicobacter pylori.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Helicobacter pylori (HP) infection is a common global infectious disease, which is an&#xD;
      important cause of chronic gastritis, peptic ulcer and gastric cancer.&#xD;
&#xD;
      At present, due to the non-standard Helicobacter pylori eradication program in clinical work,&#xD;
      poor patient compliance and other reasons, the phenomenon of HP eradication treatment failure&#xD;
      is more and more common. However, there is still no conclusion on the most appropriate time&#xD;
      for remedial treatment in patients with Hp eradication failure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Months</target_duration>
  <primary_outcome>
    <measure>The most suitable re-eradication time</measure>
    <time_frame>1year</time_frame>
    <description>The most suitable re-eradication time will be assessed by paired comparison method .</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Helicobacter Pylori</condition>
  <arm_group>
    <arm_group_label>Amoxicillin-Levofloxacin-Esomeprazole-containing quadruple group</arm_group_label>
    <description>Patients in amoxicillin-levofloxacin-esomeprazole-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and levofloxacin 500mg po qd for 14d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amoxicillin-Furazolidone-Esomeprazole-containing quadruple group</arm_group_label>
    <description>Patients in amoxicillin-furazolidone-esomeprazole-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tetracycline-Furazolidone-Esomeprazole-containing quadruple group</arm_group_label>
    <description>Patients in tetracycline-furazolidone-esomeprazole-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid, tetracycline 500mg po qid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group</arm_group_label>
    <description>Patients in amoxicillin-levofloxacin-vonoprazan fumarate-containing quadruple group will receive vonoprazan fumarate 20mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and levofloxacin 500mg po qd for 14d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group</arm_group_label>
    <description>Patients in amoxicillin-furazolidone-vonoprazan fumarate-containing quadruple group will receive vonoprazan fumarate 20mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group</arm_group_label>
    <description>Patients in tetracycline-furazolidone-vonoprazan fumarate-containing quadruple group will receive vonoprazan fumarate 20mg po bid, tetracycline 500mg po qid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin , Levofloxacin and Esomeprazole</intervention_name>
    <description>Esomeprazole-Bismuth-Amoxicillin-Levofloxacin-containing quadruple regimens</description>
    <arm_group_label>Amoxicillin-Levofloxacin-Esomeprazole-containing quadruple group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin , Furazolidone and Esomeprazole</intervention_name>
    <description>Esomeprazole-Bismuth-Amoxicillin-Furazolidone-containing quadruple regimens</description>
    <arm_group_label>Amoxicillin-Furazolidone-Esomeprazole-containing quadruple group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracycline , Furazolidone and Esomeprazole</intervention_name>
    <description>Esomeprazole-Bismuth-Tetracycline-Furazolidone-containing quadruple regimens</description>
    <arm_group_label>Tetracycline-Furazolidone-Esomeprazole-containing quadruple group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin,Levofloxacin and Vonoprazan fumarate</intervention_name>
    <description>Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group</description>
    <arm_group_label>Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin,Furazolidone and Vonoprazan fumarate</intervention_name>
    <description>Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group</description>
    <arm_group_label>Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracycline,Furazolidone and Vonoprazan fumarate</intervention_name>
    <description>Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group</description>
    <arm_group_label>Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patients in Shandong province,aged between 18 and 70 years old, with positive H. pylori&#xD;
        infection that was eradicated by previous therapies but failed are included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients, aged between 18 and 70 years old, with positive H. pylori infection that was&#xD;
             eradicated by previous therapies but failed are included. The H. pylori infection is&#xD;
             confirmed by the positive rapid urease test or 13C-breath test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with significant underlying disease including liver, cardiac, pulmonary, and&#xD;
             renal diseases, neoplasia, coagulopathy and genetic diseases, history of gastric&#xD;
             surgery, pregnancy, breast-feeding, active gastrointestinal bleeding, the use of PPI,&#xD;
             NSAID or antibiotics during the 4 weeks prior to enrolment, and previous history of&#xD;
             allergic reactions to any of the medications used in this protocol. Patients&#xD;
             previously treated with H. pylori eradication regimens or those unwilling to&#xD;
             participate in the study were also excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiuli Zuo, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiuli Zuo, MD,PhD</last_name>
    <phone>15588818685</phone>
    <phone_ext>053188369277</phone_ext>
    <email>zuoxiuli@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>257000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuli Zuo, MD,PhD</last_name>
      <phone>15588818685</phone>
      <phone_ext>053188369277</phone_ext>
      <email>zuoxiuli@sina.com</email>
    </contact>
    <investigator>
      <last_name>Junnan Hu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yueyue Li, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Minjuan Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 21, 2021</study_first_submitted>
  <study_first_submitted_qc>March 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>October 10, 2021</last_update_submitted>
  <last_update_submitted_qc>October 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Xiuli Zuo</investigator_full_name>
    <investigator_title>Professor, Director of gastroenterology department of Qilu hospital</investigator_title>
  </responsible_party>
  <keyword>Re-eradication time</keyword>
  <keyword>Remedial treatment</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
    <mesh_term>Furazolidone</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

